三葉草生物-B(02197.HK):接種一劑新冠候選疫苗SCB-2019對預防嚴重肺炎保護力爲89.7%
三葉草生物-B(02197.HK)公佈三聚體重組蛋白及已添加佐劑的候選新冠疫苗的保護效力及安全性研究數據,與既往未感染新冠病毒的安慰劑組受試者相比,既往感染新冠病毒的個體接種一劑和兩劑新冠候選疫苗SCB-2019後對預防任何嚴重程度的新冠肺炎的累積保護效力分別爲89.7%和93.8%。
在既往感染新冠病毒的人羣中,接種一劑和兩劑SCB-2019與安慰劑組相比較,接種一劑降低了任何嚴重程度新冠肺炎的風險49.9%,和兩劑降低了64.2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.